A Phase II Study of Dasatinib in Patients with Chemosensitive Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30602)
- 1 March 2010
- journal article
- research article
- Published by Elsevier BV in Journal of Thoracic Oncology
- Vol. 5 (3), 380-384
- https://doi.org/10.1097/jto.0b013e3181cee36e
Abstract
No abstract availableThis publication has 22 references indexed in Scilit:
- Synergistic cell growth inhibition by the combination of amrubicin and Akt-suppressing tyrosine kinase inhibitors in small cell lung cancer cells: Implication of c-Src and its inhibitorInternational Journal of Oncology, 2009
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- Small Cell Lung Cancer: Have We Made Any Progress Over the Last 25 Years?The Oncologist, 2007
- Changing Epidemiology of Small-Cell Lung Cancer in the United States Over the Last 30 Years: Analysis of the Surveillance, Epidemiologic, and End Results DatabaseJournal of Clinical Oncology, 2006
- Dasatinib (BMS-354825), a Dual SRC/ABL Kinase Inhibitor, Inhibits the Kinase Activity of Wild-Type, Juxtamembrane, and Activation Loop Mutant KIT Isoforms Associated with Human MalignanciesCancer Research, 2006
- A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG studyAnnals of Oncology, 2005
- Discovery of N-(2-Chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a Dual Src/Abl Kinase Inhibitor with Potent Antitumor Activity in Preclinical AssaysJournal of Medicinal Chemistry, 2004
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Expression of pp60c-src in human small cell and non-small cell lung carcinomasEuropean Journal of Cancer, 1992
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958